A Phase 1/2a Dose Escalation Study of AST-OPC1 in Subjects With Subacute Cervical Spinal Cord Injury
Phase of Trial: Phase I/II
Latest Information Update: 09 Aug 2017
At a glance
- Drugs OPC 1 (Primary)
- Indications Spinal cord injuries
- Focus Adverse reactions; Proof of concept
- Acronyms SCi-STAR; SCiSTAR
- Sponsors Asterias Biotherapeutics
- 09 Aug 2017 According to an Asterias Biotherapeutics media release, company plans to increase trial sites from 8 to 12.
- 09 Aug 2017 According to an Asterias Biotherapeutics media release, enrollment for entire trial is expected to complete by the end of 2017, and multiple safety and efficacy readouts are expected during the remainder of 2017 and 2018.
- 09 Aug 2017 According to an Asterias Biotherapeutics media release, first patient in the fifth and final cohort of this trial has been dosed.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History